{
  "id": 20893821,
  "title": "H.C. Wainwright reiterates Halozyme stock rating after Germany ruling",
  "url": "https://urgent.news/2026/11/20/h-c-wainwright-reiterates-halozyme-stock-rating-after-germany-ruling",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-20T12:00:51.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-halozyme-stock-rating-after-germany-ruling-93CH-5041458"
  },
  "original_language": "en",
  "account": "H.C. Wainwright has maintained its Buy rating and $130.00 price target for Halozyme Therapeutics (NASDAQ:HALO) following a German court ruling that may affect the company's patent position. The stock is currently trading at $93.04, down 7.2% over the past week, although InvestingPro analysis indicates the shares are undervalued at a Fair Value of $108.40. Munich's appeals court recently lifted a preliminary injunction that had blocked Keytruda SC in Germany, weakening Halozyme's leverage with Merck and potentially reducing settlement upside. The ruling could have implications for other European courts, according to the firm. A separate Dutch order covering eight markets, including France and Italy, remains in place. H.C. Wainwright's valuation does not include potential Merck settlement royalties and accounts for existing royalties under separate ENHANZE intellectual property. The firm's 12-month price target remains at $130 per share. Halozyme Therapeutics also reported impressive third-quarter 2026 results, surpassing analyst expectations with adjusted earnings of $2.39 per share and revenue of $492.97 million. Despite these positive results, the stock declined, possibly due to valuation concerns. Analyst activity varied, with TD Cowen maintaining a Buy rating and Morgan Stanley downgrading the stock.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}